CALR | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

24 November 2025

ASH 2025 preview – a new menin battleground

Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.

Subscribe to CALR